Novo Nordisk Plans to Open a Tech Headquarters in Spain

Novo Nordisk bets on Spain. The Danish pharmaceutical company has announced that it will create a technological and digital center in Madrid that will serve as the necessary support to support the rest of the activities that the company develops on a global scale, according to El Economista. This decision was made more than a year ago and it is expected that the operation will begin to materialize as soon as possible.

According to the same media, the firm has already incorporated 19 specialist professionals in the areas of data management and biostatistics for the development of clinical trials. Novo Nordisk has sixteen production plants spread across nine international capitals and ten research and development centers in five countries (China, Denmark, India, the United Kingdom, and the United States), which are expected to be joined by Spain soon.

Although 39% of the company’s employees are located in Denmark, the pharmaceutical company maintains a firm international commitment. In this segment, the company’s sales reached 24,070 million Danish crowns (€3. 23 million ) in the first quarter of 2023, which represents an increase of 9% compared to the same period of the previous year.

Currently, Novo Nordisk has ten research and development centers spread across five countries

In addition to this operation, Novo Nordisk announced yesterday the adhesion with the firm Forética, an organization dedicated to sustainability and corporate social responsibility in Spain. Rodrigo Gribble, general director and corporate vice president of Novo Nordisk in Spain, assured that “the company has been integrating an environmental approach in all its activities for decades and the incorporation of Forética represents another significant step in our commitment to continue promoting the path towards a sustainable future.”

The Danish pharmaceutical company increased its profit by 42.5% in the first half of 2023, reaching 39,242 million Danish crowns (€5.26 million). The firm has decided to increase its forecasts for the end of the year and predicts that its operating profit will grow between 31% and 37% compared to the same period of the previous year, compared to the development of 28 and 34% that it estimated in the last forecast.

In the first six months of the year, net sales reached 107,667 million Danish crowns (€14.45 million), 29% more than during the same period of the previous year. Specifically, Novo Nordisk has announced that the increase has been a consequence, mainly, of the growth in sales of Wegovy, which, reaching a turnover of 12,081 million Danish crowns (€1.62 million), has more than quadrupled compared to the latest results.

__

(Featured image by Jonny_Joka via Pixabay)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in PlantaDoce. A third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.